Citrate versus heparin anticoagulation in continuous renal replacement therapy in small children
| Autor: | Josephus P. J. van Gestel, Roelie M. Wösten-van Asperen, Esther S. Veldhoen, P. Raymakers-Janssen, Ingrid A. van Kessel, Marc R. Lilien |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2017 |
| Předmět: |
Nephrology
Male Continuous renal replacement therapy Time Factors medicine.medical_treatment 030232 urology & nephrology 030204 cardiovascular system & hematology Pediatrics chemistry.chemical_compound 0302 clinical medicine Prospective Studies Prospective cohort study Children Anticoagulant Acute kidney injury Heparin Acute Kidney Injury Water-Electrolyte Balance Perinatology Renal Replacement Therapy and Child Health Intensive Care Units Treatment Outcome Anesthesia Child Preschool Female Original Article Citric acid medicine.drug medicine.medical_specialty medicine.drug_class Critical Illness Citric Acid 03 medical and health sciences Anticoagulation Internal medicine medicine Journal Article Humans Pediatrics Perinatology and Child Health Renal replacement therapy Adverse effect Blood Coagulation business.industry Anticoagulants Infant medicine.disease Surgery chemistry Pediatrics Perinatology and Child Health business Citrate |
| Zdroj: | Pediatric Nephrology (Berlin, Germany) Pediatric Nephrology, 32(10), 1971. Springer Verlag |
| ISSN: | 0931-041X |
| DOI: | 10.1007/s00467-017-3694-4 |
| Popis: | Background: Citrate is preferred over heparin as an anticoagulant in adult continuous renal replacement therapy (CRRT). However, its potential adverse effects and data on use in CRRT in infants and toddlers is limited. We conducted a prospective study on using citrate in CRRT in critically ill small children. Methods: Children who underwent CRRT with the smallest filter in our PICU between November 2011 and November 2016 were included. Both heparin and citrate were applied according to a strict protocol. Our primary outcome was circuit survival time. Secondary outcomes were alkalosis, citrate toxicity, and number of red blood cell transfusions. Results: Heparin was used in six patients (121 circuits, total CRRT time 3723 h). Citrate was used in 14 patients (105 circuits, total CRRT time 4530 h). Median circuit survival time with heparin was 21 h (IQR 14.5–27.5) compared to 45.2 h (IQR 37.5–52.8) with citrate (p |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|